Retatrutide is a synthetic peptide triple agonist targeting three incretin and metabolic receptors simultaneously: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). It represents the third generation of incretin-based research compounds — after GLP-1 monoagonists (semaglutide) and GLP-1/GIP dual agonists (tirzepatide) — by adding glucagon receptor activation to the dual incretin model.
The glucagon receptor activation is the defining feature. Glucagon is classically considered a counter-regulatory hormone (opposing insulin), so activating GCGR simultaneously with GLP-1R/GIPR creates complex, context-dependent signaling that is an active area of metabolic research.
Mechanism of Action
GLP-1R activation: Insulin secretion augmentation, glucagon suppression, gastric motility slowdown, CNS satiety signaling
GIPR activation: Additional incretin effect, adipose tissue signaling, bone metabolism
GCGR activation: The novel component. In isolation, glucagon receptor activation raises blood glucose (hepatic glycogenolysis, gluconeogenesis). In combination with GLP-1R/GIPR activation, the research literature suggests a more complex metabolic picture — including potential enhancement of energy expenditure (thermogenesis), fatty acid oxidation in hepatic tissue, and effects on body composition that differ from dual agonists alone.
The hypothesis driving retatrutide research: selective GCGR agonism combined with GLP-1R/GIPR activity may achieve metabolic effects (particularly on hepatic fat metabolism) that dual agonists cannot.
Retatrutide vs. Tirzepatide vs. Semaglutide
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptors | GLP-1R + GIPR + GCGR | GLP-1R + GIPR | GLP-1R |
| Generation | Triple agonist | Dual agonist | Monoagonist |
| Research complexity | Highest | Moderate | Lowest |
| Approx. half-life | ~6 days | ~5 days | ~7 days |
| Research use | Triple receptor interaction studies | Dual incretin studies | GLP-1R reference |
Research Applications
- Triple incretin receptor pharmacology: Studying simultaneous GLP-1R + GIPR + GCGR activation
- Hepatic metabolism research: Glucagon receptor effects on hepatic glucose and lipid metabolism
- Energy expenditure models: GCGR contributions to thermogenesis in the context of incretin activation
- Comparative incretin studies: Retatrutide vs. tirzepatide vs. semaglutide in matched experimental models
- Body composition research: Differential effects on fat vs. lean mass in preclinical models
FAQs
Is retatrutide the same as tirzepatide?
No. Tirzepatide is a dual agonist (GLP-1R + GIPR). Retatrutide adds a third receptor: the glucagon receptor (GCGR). They are distinct research compounds with different receptor activity profiles.
Why would researchers use retatrutide instead of tirzepatide?
To study the added contribution of glucagon receptor activation. If a research question specifically concerns GCGR’s role in metabolic signaling — especially hepatic fat metabolism or energy expenditure — retatrutide provides that third pathway that tirzepatide lacks.
What is the molecular weight of retatrutide?
Retatrutide’s molecular weight is approximately 4,867 Da. Exact specification should be verified against the batch COA.
→ Retatrutide 15mg — Life Link Research
For research purposes only. Not for human use.